Stereotactic Arrhythmia Radiotherapy for refractory ventricular tachycardia showed six manageable severe adverse events and no treatment-related deaths in long-term follow-up.
Is Stereotactic Arrhythmia radiotherapy safe during long-term follow-up in patients with refractory ventricular tachycardia?
Patients with refractory ventricular tachycardia
Stereotactic Arrhythmia radiotherapy (STAR)
Long-term safety (treatment-related severe adverse events and deaths)safety
Stereotactic arrhythmia radiotherapy for refractory ventricular tachycardia appears to have a manageable long-term safety profile, though routine echocardiographic monitoring for valvular dysfunction and pericardial effusion is recommended.
During long-term follow-up, six manageable treatment-related severe AEs were observed, while no treatment-related deaths occurred. Although no STAR-specific dose guidance could yet be defined, routine echocardiographic follow-up focused at valvular dysfunction and pericardial effusion are recommended. Larger, prospective studies are needed to further define the long-term safety profile of STAR and to develop evidence-based dose guidance and follow-up recommendations.
Building similarity graph...
Analyzing shared references across papers
Loading...
Wiert F. Hoeksema
Martijn H. van der Ree
Jorrit S. Visser
Radiotherapy and Oncology
University of Amsterdam
University of Lausanne
University Hospital of Lausanne
Building similarity graph...
Analyzing shared references across papers
Loading...
Hoeksema et al. (Sun,) reported a other. Stereotactic Arrhythmia Radiotherapy for refractory ventricular tachycardia showed six manageable severe adverse events and no treatment-related deaths in long-term follow-up.
www.synapsesocial.com/papers/698ebeb185a1ff6a93015fc4 — DOI: https://doi.org/10.1016/j.radonc.2026.111435